FDA Approves EOHILIA For Treating EoE in The US

FDA approves Takeda's EOHILIA® for treating Eosinophilic Oesophagitis (EoE). Learn more about the medication's mechanism of action. Read more

FDA Approves Dupixent As EoE Treatment For Children From One to Eleven

FDA has approved Dupixent (dupilumab) for children aged one to eleven, an important step for EoE management in young children and families. Read more

Maternal and Infant Antibiotic and Acid Suppressant Use and Risk of Eosinophilic Oesophagitis

New research reveals that the use of antibiotics and acid suppressants by mothers and infants may increase the risk of developing Eosinophilic Oesophagitis. Read more

Pollen Season and EoE: How It Affects Diet Treatment

Pollen season can lower the response rate to the six-food elimination diet (SFED) in patients with Eosinophilic Oesophagitis (EoE), study shows. Read more

A New Study Shows the Potential of Blood Biomarkers for Eosinophilic Oesophagitis

This study sheds light on non-invasive blood biomarkers to potentially diagnose and manage Eosinophilic Oesophagitis. Read more

Eosinophilic Oesophagitis and Asthma: A Revealing Connection in Hospital Visits

A study shows that patients with eosinophilic oesophagitis (EoE) and asthma seek hospital care earlier than those with only one condition. Read more

EOS Network at 75th BSACI Conference: Networking and Advancements in Eosinophilic Diseases

EOS Network attended the 75th BSACI Conference to connect with healthcare professionals and advocate for EoE awareness. Read more

FDA Grants Priority Review for Dupixent (dupilumab) in Treating Eosinophilic Oesophagitis in Children

Learn more about Dupixent and what impact its approval could have on treating EoE in younger children. Read more

Health Disparities in Children with Eosinophilic Oesophagitis

Learn more about differences existing in care for children with eosinophilic oesophagitis, depending on race, urbanisation, and socioeconomic status. Read more

Takeda's Resubmission of EoE Drug For FDA Approval

FDA to review Takeda's resubmission of Budesonide oral suspension - NDA of TAK-721, offering new hope for Eosinophilic Oesophagitis (EoE) patients. What does this mean for the eosinophilic community? Read more

Study: Weekly Doses of Dupilumab Are The Most Effective at Managing Eosinophilic Oesophagitis

Recent research shows weekly dupilumab outperforms bi-weekly treatments in managing Eosinophilic Oesophagitis (EoE) symptoms. Read more

TSLP: A Pathway to Non-Invasive Blood Tests and Targeted Treatments

Learn how groundbreaking research on Thymic Stromal Lymphopoietin (TSLP) offers hope for more effective and less invasive diagnoses and treatments for eosinophilic diseases like EoE. Read more

Overcoming The Inequalities in Eosinophilic Gastrointestinal Disease Research

Learn how CEGIR promotes diversity, equity, inclusion, and accessibility in research and treatments for people with Eosinophilic-associated Diseases. Read more

Achalasia's Association with Eosinophilic Oesophagitis and Other Allergic Diseases

Recent findings highlight an association between achalasia and Eosinophilic Oesophagitis (EoE) in 6.5% of achalasia patients. Understanding this rare link may improve treatment options for both conditions, potentially benefiting those with EoE and achalasia. Read more

Defining EoE Phenotypes Using Functional Lumen Imaging Probe (FLIP)

Explore new research findings on how FLIP panometry can be used to classify Eosinophilic Esophagitis (EoE) patients by disease severity. This innovative method could pave the way for personalised treatment plans, improving patient outcomes. Read more

Amino Acid-Based Elemental Diet in Eosinophilic Gastritis and Gastroenteritis: Results and Concerns

A new study highlights the effectiveness of an amino acid-based elemental diet in managing eosinophilic gastrointestinal disorders, calling for further dietary therapy research. Read more

Fluticasone Propionate Orally Disintegrating Tablet for Eosinophilic Esophagitis

Discover the efficacy of fluticasone oral disintegrating tablet in treating eosinophilic esophagitis (EoE) based on a randomised phase 2 controlled trial. Read more

New Insights into Eosinophilic Esophagitis: The Role of Type II IL-4 Receptor

A study reveals the importance of IL-13 signalling in Eosinophilic Oesophagitis (EoE) and suggests potential new treatment approaches targeting the IL-4 receptor. Read more

Impact of Dose Reduction of Topical Steroids on Adrenal Insufficiency in Paediatric Eosinophilic Esophagitis

The study shows adjusting a topical swallow steroid regimen can help manage adrenal insufficiency in children with Eosinophilic Oesophagitis EoE, but this may come at the expense of disease control. Read more

Benralizumab Shows Reduce in Eosinophil Count: A Phase 2 Trial Report

Phase 2 trial shows benralizumab induces histological remission in 77% of eosinophilic gastritis patients, but further research on other immune pathways is needed Read more

Clinical Guidance for the Use of Dupilumab in Eosinophilic Oesophagitis: A Comprehensive Approach

The latest USA guidance on the use of dupilumab in EoE. Insights into when and how to consider dupilumab as a first-line or step-up therapy, shared decision-making approach and monitoring outcomes. Read more

A New Study on Early Life Exposures as Risk Factors for Non-EoE EGIDs

A new study offers insight into the role of early life exposures like pregnancy complications or antibiotics, as risk factors for non-oesophageal eosinophilic gastrointestinal diseases (non-EoE EGIDs)​. Read more